NCT02318407View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

March 31, 2008

Conditions
Osteoarthritis
Interventions
DRUG

AMG 403

AMG 403 for the treatment of subjects with osteoarthritis

DRUG

Placebo

contains no active drug

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02318407 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain | Biotech Hunter | Biotech Hunter